Skip to content
Medical Health Aged Care, Science

Does a brain in a dish have moral rights?

Cortical Labs 3 mins read

Exploring ethical applications of bio-computing

No longer limited to the realm of science fiction, bio-computing is here, so now is the time to start considering how to research and apply this technology responsibly, an international group of experts says.

The inventors of DishBrain have partnered with bioethicists and medical researchers to map such a framework to help define and address the problem in a paper published in Biotechnology Advances.

“Combining biological neural systems with silicon substrates to produce intelligence-like behaviour has significant promise, but we need to proceed with the bigger picture in mind to ensure sustainable progress,” says lead author Dr Brett Kagan, Chief Scientific Officer of biotech start-up Cortical Lab. The group were made famous by their development of DishBrain – a collection of 800,000 living brain cells in a dish that learnt to play Pong.

While philosophers have for centuries pondered concepts of what makes us human or conscious, co-author and Uehiro Chair in Practical Ethics at the University of Oxford, Professor Julian Savulescu, warns of the urgency to determine practical answers to these questions.

“We haven’t adequately addressed the moral issues of what is even considered ‘conscious’ in the context of today’s technology,” he says.

“As it stands, there are still many ways of describing consciousness or intelligence, each raising different implications for how we think about biologically based intelligent systems.”

The paper cites early English philosopher Jeremy Bentham who argued that, with respect to the moral status of animals, “the question is not, ‘can they reason?’ nor, ‘can they talk?’ but, ‘can they suffer?’”.

“From that perspective, even if new biologically based computers show human-like intelligence, it does not necessarily follow that they have moral status,” says co-author Dr Tamra Lysaght, Director of Research at the Centre for Biomedical Ethics, National University of Singapore.

“Our paper doesn’t attempt to definitively answer the full suite of moral questions posed by bio-computers, but it provides a starting framework to ensure that the technology can continue to be researched and applied responsibly,” says Dr Lysaght.

The paper further highlights the ethical challenges and opportunities offered by DishBrain’s potential to greatly accelerate our understanding of diseases such as epilepsy and dementia.

“Current cell lines used in medical research predominately have European-type genetic ancestry, potentially making it harder to identify genetic-linked side effects,” says co-author Dr Christopher Gyngell, Research Fellow in biomedical ethics from the Murdoch Children’s Research Institute and The University of Melbourne.

“In future models of drug screening, we have the chance to make them more sufficiently representative of the real-world patients by using more diverse cell lines, and that means potentially faster and better drug development.”

The researchers point out that it is worth working through these moral issues, as the potential impact of bio-computing is significant.

“Silicon-based computing is massively energy-hungry with a supercomputer consuming millions of watts of energy. By contrast, the human brain uses as little as 20 watts of energy – biological intelligences will show similar energy efficiency,” says Dr Kagan.

“As it stands, the IT industry is a massive contributor to carbon emissions. If even a relatively small number of processing tasks could be done with bio-computers, there is a compelling environmental reason to explore these alternatives.”

Media kit with photos at www.scienceinpublic.com.au/corticallabs.
The paper is available at https://www.sciencedirect.com/science/article/pii/S0734975023001404.

Abstract

The technology, opportunities, and challenges of Synthetic Biological Intelligence

Brett J. Kagan a,, Christopher Gyngellb,c, Tamra Lysaghtd, Victor M. Coled, Tsutomu Sawaie,f, Julian Savulescub,c,d,g

a Cortical Labs, Melbourne, VIC, Australia
b Murdoch Children's Research Institute, Melbourne, VIC, Australia
c The University of Melbourne, Melbourne, VIC, Australia
d Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
e Graduate School of Humanities and Social Sciences, Hiroshima University, Hiroshima, Japan
f Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan
g Oxford Uehiro Centre for Practical Ethics, Faculty of Philosophy, University of Oxford, Oxford, United Kingdom

Abstract

Integrating neural cultures developed through synthetic biology methods with digital computing has enabled the early development of Synthetic Biological Intelligence (SBI).

Recently, key studies have emphasized the advantages of biological neural systems in some information processing tasks. However, neither the technology behind this early development, nor the potential ethical opportunities or challenges, have been explored in detail yet. Here, we review the key aspects that facilitate the development of SBI and explore potential applications.

Considering these foreseeable use cases, various ethical implications are proposed. Ultimately, this work aims to provide a robust framework to structure ethical considerations to ensure that SBI technology can be both researched and applied responsibly.


Contact details:

Tom Carruthers, Australian media contact, +61 404 404 026, tom@scienceinpublic.com.au

Brett Kagan, Chief Scientific Officer, Cortical Labs, +61 434 688 983, Brett@corticallabs.com

Media

More from this category

  • Medical Health Aged Care
  • 13/09/2024
  • 12:40
Zenas BioPharma

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading…

  • Medical Health Aged Care
  • 13/09/2024
  • 12:31
Dementia Australia

New report reinforces dementia as chronic disease of 21st century

Updates to the Dementia in Australia report, released today by the Australian Institute of Health and Welfare (AIHW), reinforce that dementia is an urgent public health issue. Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 and over. Dementia Australia CEO Professor Tanya Buchanan saidthe report highlights the enormity and impact of dementia in Australia as the chronic disease of the 21st century. “Despite the growing number of Australians diagnosed with dementia – there…

  • Medical Health Aged Care, Science
  • 13/09/2024
  • 11:08
La Trobe University

Centre to play key role in global AI medical research

Artificial intelligence promises to unlock new cures for cancer and other diseases by revolutionising the speed, cost and availability of personally designed drugs and enabling these to be tested on “digital twins" before being given to patients. AI will enable broad-spectrum like chemotherapy to be replaced by these more personalised, better targeted treatments. Scientists at La Trobe University's new Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI), launched today, will also apply AI techniques to mRNA therapy development to enable faster design of more precise and effective treatments. Vice-Chancellor Professor Theo Farrell said ACAMI would sit within La Trobe’s…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.